Hormonal
Intermittent fasting during Ramadan significantly improves insulin sensitivity and reduces insulin resistance in healthy young men, independent of changes in fasting plasma glucose.
For healthy young men, observing Ramadan-style intermittent fasting (sunrise to sunset) for about a month can improve how your body handles insulin, even if your fasting blood sugar numbers don't change. This benefit comes from reduced insulin levels and weight loss, provided you maintain your usual activity level.
Our results demonstrate that fasting during Ramadan decreases the concentration of HDL-c without any significant changes in total cholesterol, TG, and LDL-c levels... The results of the present study also demonstrate that intermittent fasting during Ramadan may lead to concomitant beneficial effects by improving insulin sensitivity and reducing insulin resistance.
Why this rating
Single-arm observational study with no control group and small sample size (n=27).
Source
Intermittent Fasting During Ramadan Improves Insulin Sensitivity and Anthropometric Parameters in Healthy Young Muslim Men
Guntari Prasetya et al. · American Journal of Lifestyle Medicine · 2018
DOI 10.1177/1559827618815430
More from this paper
- Intermittent fasting during Ramadan leads to significant reductions in body weight, BMI, fat mass, and waist circumference in healthy young men, primarily driven by negative energy balance.Moderate
- Intermittent fasting during Ramadan significantly reduces serum leptin levels in healthy young men, correlating with weight loss, while adiponectin levels remain largely unchanged.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →